Cartesian Therapeutics (RNAC) Long-Term Deferred Tax (2017)

Cartesian Therapeutics (RNAC) posted quarterly Long-Term Deferred Tax of $300000.0 for Q1 2017.

Cartesian Therapeutics (RNAC) Long-Term Deferred Tax (2017) Analysis & Trends

Cartesian Therapeutics (RNAC) has reported Long-Term Deferred Tax for 1 consecutive years, with $300000.0 the latest figure, recorded in Q1 2017.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Cartesian Therapeutics	265.54 Mn	265.54 Mn	-

Download Data

Date	Value
Mar 31, 2017	300,000.00